PriceTargets.com logo

Correvio Pharma - CORV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.42 As of 05/27/2020 01:00 AM ET
+0 (0.00%)
Get New Correvio Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CORV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CORV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Correvio Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.42.

This chart shows the closing price for CORV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Correvio Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2019Bloom BurtonUpgradeSell ➝ HoldHigh
12/11/2019Echelon Wealth PartnersDowngradeBuy ➝ HoldHigh
12/11/2019MackieDowngradeHold$1.60High
12/11/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
12/6/2019Bloom BurtonDowngradeBuy ➝ HoldLow
11/15/2019HC WainwrightReiterated RatingBuy$7.00High
9/3/2019Cantor FitzgeraldInitiated CoverageOverweight$6.00 ➝ $6.00Low
8/15/2019HC WainwrightReiterated RatingBuy$7.00Low
(Data available from 4/23/2019 forward)

News Sentiment Rating

-0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/25/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.

Correvio Pharma

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $0.42
Low: $0.42
High: $0.42

50 Day Range

MA: $0.41
Low: $0.39
High: $0.42

52 Week Range

Now: $0.42
Low: $0.21
High: $2.79

Volume

N/A

Average Volume

5,353,682 shs

Market Capitalization

$27.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Correvio Pharma?

The following Wall Street research analysts have issued stock ratings on Correvio Pharma in the last year:
View the latest analyst ratings for CORV.

What is the current price target for Correvio Pharma?

0 Wall Street analysts have set twelve-month price targets for Correvio Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Correvio Pharma in the next year.
View the latest price targets for CORV.

What is the current consensus analyst rating for Correvio Pharma?

Correvio Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CORV.

What other companies compete with Correvio Pharma?

Other companies that are similar to Correvio Pharma include Viracta Therapeutics, Aptorum Group, Enlivex Therapeutics, Spruce Biosciences and Forte Biosciences. Learn More about companies similar to Correvio Pharma.

How do I contact Correvio Pharma's investor relations team?

Correvio Pharma's physical mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The company's listed phone number is 604-677-6905 and its investor relations email address is [email protected]. The official website for Correvio Pharma is www.correvio.com. Learn More about contacing Correvio Pharma investor relations.